Mesa Laboratories Stock News

Mesa Labs (MLAB) delivered earnings and revenue surprises of -19.05% and 13.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Mesa Laboratories, Inc. (MLAB) shares closed today at 1.3% below its 52 week high of $333.42, giving the company a market cap of $1B. The stock is currently up 0.3% year-to-date, up 15.1% over the past 12 months, and up 170.0% over the past five years. This week, the Dow Jones Industrial Average rose 0.8%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 71.7% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -49.8% The company's stock price performance over the past 12 months lags the peer average by -49.8% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -17683.1% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Mesa Laboratories, Inc. (MLAB) shares closed today at 0.9% below its 52 week high of $331.90, giving the company a market cap of $1B. The stock is currently up 15.0% year-to-date, up 15.7% over the past 12 months, and up 161.1% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 43.0% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -46.6% The company's stock price performance over the past 12 months lags the peer average by -49.7% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -18471.3% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Mesa Laboratories, Inc. (MLAB) shares closed today at 1.2% below its 52 week high of $331.90, giving the company a market cap of $1B. The stock is currently up 14.7% year-to-date, up 15.2% over the past 12 months, and up 161.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 0.3%. Trading Activity Trading volume this week was 56.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -44.2% The company's stock price performance over the past 12 months lags the peer average by -47.9% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -17222.7% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

These smaller healthcare companies all have 10x potential for investors.

What to Expect From the Markets In 2022

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) hit a new 52-week high on Thursday . The company traded as high as $331.90 and last traded at $318.58, with a volume of 24663 shares trading hands. The stock had previously closed at $325.55. Several research firms have commented on MLAB. TheStreet upgraded shares of Mesa Laboratories from []

Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy

Equities research analysts forecast that Mesa Laboratories, Inc. (NASDAQ:MLAB) will report earnings per share (EPS) of $1.55 for the current quarter, according to Zacks. Two analysts have provided estimates for Mesa Laboratories earnings. The lowest EPS estimate is $1.27 and the highest is $2.09. Mesa Laboratories posted earnings of $1.46 per share during the same []

Related Stocks: MLAB ,

Cubist Systematic Strategies LLC reduced its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 73.2% in the second quarter, Holdings Channel.com reports. The institutional investor owned 755 shares of the medical instruments suppliers stock after selling 2,059 shares during the period. Cubist Systematic Strategies LLCs holdings in Mesa Laboratories were worth $205,000 at the end of []

Equities analysts expect Mesa Laboratories, Inc. (NASDAQ:MLAB) to announce $1.55 earnings per share for the current quarter, according to Zacks. Two analysts have made estimates for Mesa Laboratories earnings, with the highest EPS estimate coming in at $2.09 and the lowest estimate coming in at $1.27. Mesa Laboratories reported earnings per share of $1.46 in []

Wall Street analysts predict that Mesa Laboratories, Inc. (NASDAQ:MLAB) will announce $48.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Mesa Laboratories earnings. The lowest sales estimate is $47.80 million and the highest is $48.80 million. Mesa Laboratories posted sales of $34.17 million in the []

Mesa Laboratories, Inc. (NASDAQ:MLAB) Director John James Sullivan sold 5,192 shares of the companys stock in a transaction dated Monday, November 15th. The shares were sold at an average price of $308.02, for a total value of $1,599,239.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at []

Mesa Laboratories, Inc. (NASDAQ:MLAB) CFO John Sakys sold 1,000 shares of the companys stock in a transaction that occurred on Thursday, November 11th. The stock was sold at an average price of $317.12, for a total transaction of $317,120.00. The sale was disclosed in a document filed with the SEC, which is available at the []